Benedikt Hofauer1, Armin Steffen2, Andreas Knopf3, Katrin Hasselbacher2, Clemens Heiser3. 1. Otorhinolaryngology/Head and Neck Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. b.hofauer@tum.de. 2. Otorhinolaryngology/Head and Neck Surgery, University of Luebeck, Luebeck, Germany. 3. Otorhinolaryngology/Head and Neck Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
Abstract
OBJECTIVE: Selective upper airway stimulation (sUAS) is a new treatment modality for patients with obstructive sleep apnea (OSA) and continuous positive airway pressure (CPAP) failure. The aim of this study was to analyze therapy adherence and to structure patient experience reports. METHODS: Patients from two German implantation centers were included. Besides demographic and OSA characteristics of that cohort, patients answered a questionnaire on subjective sensation of the stimulation, use of different functions, side effects, and an inventory for the description of the attitude towards sUAS. The use of the sUAS was evaluated as a read-out of the implanted system. RESULTS: The overall apnea-hypopnea-index (AHI) of that 102 assessed patients reduced from initially 32.8/h to 12.6/h at the last available assessment. The responder rate was 75%. There was an objective therapy usage of 5.7 h and subjective reports of 6.8 nights per week. The attitude resulted in strong agreement towards the statement "UAS reduces the problems caused by my sleep apnea". Information on sensing the stimulation and usage habits could be gathered such as that stimulation is only sensed by 67.9% of the patients upon waking in the morning and that 73.6% of the patients do not change the voltage in general. CONCLUSION: This investigation on the sUAS therapy revealed a high adherence to the therapy. The AHI or daytime sleepiness do not have obvious influence on adherence. Patients expressed a positive attitude towards sUAS. These patient reports upon stimulation experiences are of great help to consult candidates for sUAS in future.
OBJECTIVE: Selective upper airway stimulation (sUAS) is a new treatment modality for patients with obstructive sleep apnea (OSA) and continuous positive airway pressure (CPAP) failure. The aim of this study was to analyze therapy adherence and to structure patient experience reports. METHODS:Patients from two German implantation centers were included. Besides demographic and OSA characteristics of that cohort, patients answered a questionnaire on subjective sensation of the stimulation, use of different functions, side effects, and an inventory for the description of the attitude towards sUAS. The use of the sUAS was evaluated as a read-out of the implanted system. RESULTS: The overall apnea-hypopnea-index (AHI) of that 102 assessed patients reduced from initially 32.8/h to 12.6/h at the last available assessment. The responder rate was 75%. There was an objective therapy usage of 5.7 h and subjective reports of 6.8 nights per week. The attitude resulted in strong agreement towards the statement "UAS reduces the problems caused by my sleep apnea". Information on sensing the stimulation and usage habits could be gathered such as that stimulation is only sensed by 67.9% of the patients upon waking in the morning and that 73.6% of the patients do not change the voltage in general. CONCLUSION: This investigation on the sUAS therapy revealed a high adherence to the therapy. The AHI or daytime sleepiness do not have obvious influence on adherence. Patients expressed a positive attitude towards sUAS. These patient reports upon stimulation experiences are of great help to consult candidates for sUAS in future.
Authors: Nick A Antic; Peter Catcheside; Catherine Buchan; Michael Hensley; Matthew T Naughton; Sharn Rowland; Bernadette Williamson; Samantha Windler; R Doug McEvoy Journal: Sleep Date: 2011-01-01 Impact factor: 5.849
Authors: Clemens Heiser; Phillippe Fthenakis; Alexander Hapfelmeier; Sebastian Berger; Benedikt Hofauer; Winfried Hohenhorst; Eberhard F Kochs; Klaus J Wagner; Guenther M Edenharter Journal: Sleep Breath Date: 2017-03-31 Impact factor: 2.816
Authors: Ferran Barbé; Joaquín Durán-Cantolla; Manuel Sánchez-de-la-Torre; Montserrat Martínez-Alonso; Carmen Carmona; Antonia Barceló; Eusebi Chiner; Juan F Masa; Mónica Gonzalez; Jose M Marín; Francisco Garcia-Rio; Josefa Diaz de Atauri; Joaquín Terán; Mercedes Mayos; Mónica de la Peña; Carmen Monasterio; Felix del Campo; Josep M Montserrat Journal: JAMA Date: 2012-05-23 Impact factor: 56.272
Authors: R Doug McEvoy; Nick A Antic; Emma Heeley; Yuanming Luo; Qiong Ou; Xilong Zhang; Olga Mediano; Rui Chen; Luciano F Drager; Zhihong Liu; Guofang Chen; Baoliang Du; Nigel McArdle; Sutapa Mukherjee; Manjari Tripathi; Laurent Billot; Qiang Li; Geraldo Lorenzi-Filho; Ferran Barbe; Susan Redline; Jiguang Wang; Hisatomi Arima; Bruce Neal; David P White; Ron R Grunstein; Nanshan Zhong; Craig S Anderson Journal: N Engl J Med Date: 2016-08-28 Impact factor: 91.245
Authors: Patrick J Strollo; M Boyd Gillespie; Ryan J Soose; Joachim T Maurer; Nico de Vries; Jason Cornelius; Ronald D Hanson; Tapan A Padhya; David L Steward; B Tucker Woodson; Johan Verbraecken; Olivier M Vanderveken; Mark G Goetting; Neil Feldman; Frédéric Chabolle; M Safwan Badr; Winfried Randerath; Kingman P Strohl Journal: Sleep Date: 2015-10-01 Impact factor: 5.849
Authors: Markus Wirth; Daniel Unterhuber; Franziska von Meyer; Benedikt Hofauer; Armin Ott; Guenther Edenharter; Danny J Eckert; Clemens Heiser Journal: J Clin Sleep Med Date: 2020-01-13 Impact factor: 4.062
Authors: Faith S Luyster; Quan Ni; Kent Lee; Christine Harrison; Vaibhav H Ramprasad; Ryan J Soose; Patrick J Strollo Journal: J Clin Sleep Med Date: 2022-09-01 Impact factor: 4.324
Authors: Francesco Gambino; Marta Maria Zammuto; Alessandro Virzì; Giosafat Conti; Maria Rosaria Bonsignore Journal: Intern Emerg Med Date: 2022-04-23 Impact factor: 5.472
Authors: Armin Steffen; Clemens Heiser; Wolfgang Galetke; Simon-Dominik Herkenrath; Joachim T Maurer; Eck Günther; Boris A Stuck; Holger Woehrle; Jan Löhler; Winfried Randerath Journal: Eur Arch Otorhinolaryngol Date: 2021-06-21 Impact factor: 2.503